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The basic drugs doxorubicin and mitoxantrone are known to be concentrated in acidic endosomes of cells. Here, we address the
hypotheses that raising endosomal pH with the modifying agents chloroquine, omeprazole or bafilomycin A might decrease
sequestration of anticancer drugs in endosomes, thereby increasing their cytotoxicity and availability for tissue penetration.
Chloroquine, omeprazole and bafilomycin A showed concentration-dependent effects to raise endosomal pH, and to inhibit
sequestration of doxorubicin in endosomes. Chloroquine and omeprazole but not bafilomycin A decreased the net uptake of
doxorubicin into cells, but there was no significant effect on uptake of mitoxantrone. Omeprazole and bafilomycin A increased the
cytotoxicity of the anticancer drugs for cultured cells, as measured in a clonogenic assay, whereas chloroquine had minimal effects on
cytotoxicity despite reduced uptake of doxorubicin. Omeprazole but not chloroquine or bafilomycin A increased the penetration of
anticancer drugs through multicellular layers of tumour tissue. We conclude that modifiers of endosomal pH might increase
therapeutic effectiveness of basic drugs by increasing their toxicity and/or tissue penetration in solid tumours.
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Most studies on causes of the limited success of chemotherapy for
solid tumours have concentrated on cellular and molecular
properties of tumour cells that lead to intrinsic or acquired drug
resistance. While these mechanisms are important, solid tumours
have a poorly formed vasculature and an additional explanation
for the lack of effectiveness of many anticancer drugs may be their
limited ability to penetrate through multiple cell layers of the
extravascular space to reach all of the tumour cells (Durand, 1989;
Jain, 1990; Hicks et al, 1997; Phillips et al, 1998; Lankelma et al,
1999; Tunggal et al, 1999; Tannock et al, 2002). The multicellular
layer (MCL) model allows tumour cells to be grown in culture with
many properties of tumours in vivo, including desmosomes
between cells and an extracellular matrix (Hicks et al, 1997;
Minchinton et al, 1997; Phillips et al, 1998; Tunggal et al, 1999,
2000; Cowan and Tannock, 2001; Tannock et al, 2002). Multi-
cellular layers provide a simple, direct and quantitative means for
measuring the penetration of drugs through solid tissue. The
compound of interest is added to one side of the MCL and its
appearance on the other side is measured by appropriate analytical
methods. Using this method, we and others have demonstrated
limited penetration of several anticancer drugs through solid tissue
(Phillips et al, 1998; Tunggal et al, 1999; Tannock et al, 2002).
Strategies that decrease the uptake of drugs into cells, such as high
levels of folate in the presence of methotrexate or expression of P-
glycoprotein in the presence of doxorubicin were found to increase
tissue penetration, suggesting that tissue penetration is largely
through the extracellular matrix (Tunggal et al, 2000; Cowan and
Tannock, 2001).
Basic compounds such as doxorubicin and mitoxantrone are
membrane permeable in their neutral form but relatively imperme-
able when protonated. Inside cells, basic drugs enter acidic cellular
compartments, such as endosomes, where they become protonated
and are sequestered (Mayer et al, 1986; Schindler et al, 1996;
Hurwitz et al, 1997). In a series of papers, Simon and his co-
workers (Schindler et al, 1996; Altan et al, 1998; Simon 1999;
Rajagopal and Simon, 2003) have documented expression of
multidrug-resistance transporters on endosomal membranes, and
have shown increased sequestration of drugs in these compart-
ments in drug-resistant cells. This sequestration decreases the
availability of anticancer drugs for their cellular target (DNA in the
nucleus). Depending on the rate of recycling of endosomes to fuse
with the plasma membrane and release their contents extracellu-
larly, it may also lead to less drug being available extracellularly for
penetration to more distant cells.
The trapping of basic drugs in the acidic compartments of cells
might be inhibited by decreasing the pH gradient across the
intracellular endosomal membranes. Here, we describe two
approaches to increasing endosomal pH by coadministration of
other agents that are in clinical use: (i) a competing basic
compound, chloroquine (used for treatment of malaria), which
enters the acidic compartments and becomes protonated, thereby
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(ii) omeprazole (used to reduce stomach acidity), which inhibits
proton pumps including that in the endosomal membrane
(Mattsson et al, 1991). We also include experiments with
bafilomycin A, a more specific inhibitor of the endosomal proton
pump (Mattsson et al, 1991), although this compound would be
too toxic to use clinically.
In the present study, we address the following hypotheses: (i)
that raising endosomal pH will decrease sequestration in endo-
somes of basic anticancer drugs such as doxorubicin and
mitoxantrone; (ii) that decreased endosomal sequestration will
increase cytotoxicity of these drugs and (iii) that decreasing
endosomal sequestration will decrease cellular uptake of the
anticancer drugs and hence allow them to better penetrate through
tumour tissue.
MATERIALS AND METHODS
Cells and drugs
Experiments were performed using the mouse mammary sarcoma
cell line, EMT-6 (obtained originally from Dr R Sutherland,
University of Rochester, Rochester, NY, USA) and the human
mammary carcinoma, MCF-7 obtained from American Type
Culture Collection (Rockville, MD, USA). Cells were grown as
monolayers in a-MEM (Sigma Chemical Co., St Louis, MO, USA)
supplemented with 10% foetal bovine serum (Cansera, Toronto,
Ontario, Canada) at 371C in a humidified atmosphere of 95% air
plus 5% CO2. Experiments on dispersed cells were performed using
exponentially growing cells. Tests were performed routinely to
ensure that cells were free of mycoplasma.
Doxorubicin and mitoxantrone were obtained from the hospital
pharmacy. Chloroquine was purchased from Sigma (St Louis, MO,
USA) and dissolved in phosphate-buffered saline. Omeprazole was
obtained in powder form from AstraZeneca (Molndal, Sweden)
and dissolved in ethanol. Bafilomycin A was obtained from Sigma
(St Louis, MO, USA) and dissolved in DMSO.
Measurement of endosomal pH
The influence of chloroquine, omeprazole and bafilomycin A on
endosomal pH was measured as follows. Cells (10
6ml
 1) were
treated with varying concentrations of these agents, or with the
vehicle solution. They were incubated for 3h with dextran-
fluorescein-tetramethylrhodamine 10000MW, anionic (FITC/
TMR-dextran, Molecular Probes, Inc., Eugene, OR, USA), which
is taken up into endosomes, followed by exposure to media for 2h.
Fluorescence was measured using a Coulter Epics Elite flow
cytometer (Beckman Coulter, Miami, FL, USA) equipped with an
argon laser emitting at 488nm. The argon laser was used to excite
FITC and TMR with emission evaluated at 525nm (pH-dependent)
and 575nm (pH-independent), respectively. Calibration of fluo-
rescence measurements was performed using the ionophore
nigericin (Sigma, St Louis, MO, USA) in buffers of known pH
(Poole and Ohkuma, 1981). This allows equilibration of all the
internal compartments of cells to the pH of the incubating buffer.
A curve was generated that demonstrated the relationship between
FITC fluorescence emission ratio and pH.
Fluorescence microscopy
The distribution of doxorubicin in cells, in the presence or absence
of agents that might influence endosomal pH, was evaluated by
fluorescence microscopy. Cells attached to a chambered cover-
glass were pretreated with chloroquine, omeprazole or bafilomycin
A and then incubated in media containing 3.5mM doxorubicin
for 2h. At the end of the incubation, the drugs were washed out
and the cover-glass was placed on the microscope stage and
fluorescence signal was recorded using a Zeiss Axiovert 200 M
fluorescence inverted microscope, equipped with a 530–560nm
excitation and a 573–647nm emission filter set. The presence of
fluorescent doxorubicin in cellular compartments was captured
with a Roper Scientific CoolSnap HQ CCD camera, and false-
coloured red.
To visualise endosomes, the cells were also exposed to the
pH-sensitive endosomal dye, LysoSensor Yellow/Blue DND-160
(Molecular Probes, Inc., Eugene, OR, USA) at a concentration of
5mM for 15min (Hurwitz et al, 1997). The fluorescent signal was
measured with excitation at 360nm and emission at 420nm and
false-coloured blue. Evidence for colocalisation of doxorubicin and
lysoSensor was sought by overlaying images of the same cells, and
seeking fusion of the colours of the two images (purple).
Drug uptake into cells
The uptake into cells of radiolabelled
14C-doxorubicin (Amersham,
England) and
3H-mitoxantrone (Moravek Chemicals, Brea, CA,
USA) was studied using a spin-through-oil technique (Keyes et al,
1987; Cowan et al, 1992). Stirred suspensions of single cells
were pretreated in the presence or absence of chloroquine or
omeprazole (100mM and 1mM) or 100nM bafilomycin A for 1h;
radiolabelled doxorubicin (0.27mM; 0.15mCi10ml
 1) or mitoxan-
trone (67nM;2 mCi10ml
 1) was then added to the suspension.
Aliquots (100ml) were removed as a function of time (up to 5h)
and layered on top of a mixture of dibutylphthalate and corn oil
(4:1) in microcentrifuge tubes. The tubes were then spun at
14000r.p.m. for 5min, and the cells were pelleted at the bottom of
the tube. The medium and then the oil were aspirated and the cell-
associated radioactivity was determined by liquid scintillation
counting.
Assessment of cytotoxicity
Cytotoxicity was evaluated by a colony-forming assay. Single cell
suspensions were treated in glass polyshell vials with 1.8mM
doxorubicin or 1mM mitoxantrone in the presence or absence of
100mM chloroquine, 100mM omeprazole or 100nM bafilomycin A.
The vials were placed in a water bath at 371C, magnetically stirred
and gassed with 95% air plus 5% CO2. Samples were removed as a
function of time up to 5h later, centrifuged, washed and plated in
serial dilution in plastic tissue culture dishes containing 5ml
medium. Colonies generated 8–14 days later were stained with
methylene blue and counted.
Penetration of drugs through MCL
Multicellular layers (MCL)were generated by seeding exponentially
growing cells on collagen-coated microporous Teflon membranes
attached to culture plate inserts (Millicell-CM inserts, 3mm pore
size, Millipore, Bedford, MA, USA). Prior to use in experiments,
the MCL were examined by a light microscope to ensure uniform
thickness. One or two randomly selected MCL per experiment were
dissociated using trypsin to determine the total number of cells;
MCL containing B3–4 10
6 cells were used in the experiments.
Solutions containing
14C-doxorubicin or
3H-mitoxantrone in 1%
agar solution were added to one side of the MCL (compartment 1)
and the membrane was then floated on a larger volume of stirred
culture media (compartment 2).
3H- or
14C-sucrose was added and
the penetration of sucrose was used as an internal control. Agar
prevents convective motion from influencing penetration proper-
ties but does not inhibit drug transport. The concentration of the
drug in compartment 2 as a function of time (up to 6h) was
measured by scintillation counting, and was expressed as a ratio
(‘relative penetration’) of that achieved after the same time interval
by penetration through the Teflon membrane in the absence of
an MCL.
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sStatistical analysis
Student’s t-test was used for the determination of statistical
significance when comparing outcome of different experimental
conditions.
RESULTS
Endosomal pH
Chloroquine, omeprazole and bafilomycin A increased the
endosomal pH in a dose-dependent manner by a maximum of
approximately two pH units in both EMT-6 (Figure 1A) and MCF-
7 cells (Figure 1B). Chloroquine was effective in changing the
endosomal pH at a lower concentration than omeprazole.
Figure 1C shows that bafilomycin A was effective in raising
endosomal pH at much lower concentration with maximal effects
observed at a concentration of about 100nM.
Cellular uptake and localisation of anticancer drugs
Fluorescence micrographs show that doxorubicin was sequestered
in a punctate pattern in the cytoplasm of both EMT-6 (Figure 2A)
and MCF-7 cells (not shown) as well as being taken up into the
nucleus, where it is known to target DNA. LysoSensor Yellow/Blue
DND-160 is known to accumulate in acidic organelles such as
endosomes (Figure 2B), and overlay experiments confirmed that
doxorubicin colocalised with this fluorescent pH indicator (not
shown). Chloroquine and omeprazole led to a reduction in
doxorubicin fluorescence in endosomes (Figures 2C and D).
Higher concentration (1mM) of omeprazole than chloroquine was
required to modify the cellular localisation of doxorubicin,
consistent with the dose–response relationships for these agents
to influence endosomal pH. Bafilomycin A at a concentration of
100nM reduced doxorubicin fluorescence in endosomes to
undetectable levels (not shown). Quantifying the amount of
fluorescent doxorubicin in cells was not possible due to its
photobleaching characteristics.
There were inconsistent effects of chloroquine or omeprazole to
influence the total cellular uptake of the radiolabelled anticancer
drugs (Figure 3). The total cellular accumulation of doxorubicin
in EMT-6 cells was reduced by coadministration of chloroquine
and by omeprazole at 100mM (Figure 3A), but (surprisingly) not
at 1mM (data not shown). Both modifiers reduced uptake of
doxorubicin into MCF-7 cells, but there was no difference in the
magnitude of the effect for concentrations of 100mM (Figure 3B)
and 1mM (not shown). There was no consistent effect for
omeprazole or chloroquine (at either concentration) to influence
the net uptake of mitoxantrone (Figure 3B and D). Bafilomycin A
(100nM) did not influence the uptake of doxorubicin into EMT-6
cells.
Cytotoxicity of anticancer drugs
Exposure of cells to chloroquine (100mM), omeprazole (100mM or
1m M) or bafilomycin A (100nM) for up to 5h was not toxic to cells,
as determined in a colony-forming assay. Omeprazole (100mM)
increased the cytotoxicity of doxorubicin for EMT-6 and MCF-7
cells, and of mitoxantrone for EMT-6 cells (Figure 4A–C), and had
marked effects to increase toxicity of doxorubicin when used at a
concentration of 1mM (data not shown). Chloroquine had minimal
effects on the cytotoxicity of doxorubicin and mitoxantrone for
both EMT-6 and MCF-7 cells (Figure 4). Bafilomycin A (100nM)
increased the cytotoxicity of doxorubicin for EMT-6 cells (data not
shown).
Tissue penetration of anticancer drugs
Previous experiments have shown that both murine EMT-6 and
human MCF-7 breast cancer cells produce MCL of consistent
thickness (B150mM). The penetration of radiolabelled mitoxan-
trone and doxorubicin through the Teflon membrane that is used
to support the growth of MCL leads to 30–40% of equilibrium
concentration in the receiving compartment at 4–6h (Tunggal
et al, 1999).
Tissue penetration relative to that through the cell-free
membrane is shown in Figure 5. Omeprazole (100mM) increased
the penetration of doxorubicin and mitoxantrone through
MCL grown from EMT-6 cells (Figure 5A and B) (Po0.05
for Figure 5B). Smaller or no changes were observed with
the penetration of doxorubicin and or mitoxantrone through
MCL grown from MCF-7 cells (Figure 5C and D). Chloroquine
(100mM) had little or no effect on penetration of doxorubicin
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Figure 1 Endosomal pH measurements in (A) EMT-6 and (B) MCF-7
cells exposed to chloroquine (m) or omeprazole (.). Also indicated are
the effects on endosomal pH of EMT-6 cells for the endosomal proton
pump inhibitor bafilomycin A (C). Means and s.e.m. are shown for at least
three independent measurements. (Where bars are not shown, s.e.m. is
less than the height of the points.)
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through MCL derived from EMT-6 cells but not those from MCF-7
cells (data not shown). Bafilomycin A (100nM) did not influence
tissue penetration.
DISCUSSION
In designing the present experiments, we established three
related hypotheses: (i) that raising endosomal pH will decrease
Doxorubicin + chloroquine Doxorubicin + omeprazole
Doxorubicin LysoSensor A B
CD
Figure 2 Fluorescent micrographs show EMT-6 cells treated with (A) doxorubicin (3.5mM), (B) the fluorescent pH indicator LysoSensor Yellow/Blue
DND-160 which accumulates in acidic organelles, (C) doxorubicin and chloroquine 100mM and (D) doxorubicin and omeprazole 1mM. Note decrease in
fluorescence in endosomes due to doxorubicin in (C and D). Similar results were obtained for MCF7 cells. Direct comparison of doxorubicin uptake is not
possible because of photobleaching.
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Figure 3 Time-dependent uptake of radiolabelled doxorubicin (A and C) and mitoxantrone (B and D) into EMT-6 cells (A and B) and MCF-7 cells (C
and D). Doxorubicin alone (K), mitoxantrone alone (’), drug plus chloroquine 100mM (m) or omeprazole 100mM (.). Mean and s.e.m. are shown for
three independent experiments. Significant effects (Po0.001, Student’s t-test) are seen for both modifiers in Figure 3A. (c.p.m.¼counts per minute in cell
pellet).
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doxorubicin and mitoxantrone; (ii) that decreased endosomal
sequestration will increase cytotoxicity of these drugs and (iii) that
decreasing endosomal sequestration will decrease net cellular
uptake of the anticancer drugs and hence allow them to better
penetrate through tumour tissue. Our results provide strong
support for the first hypothesis and partial support for the second
and third.
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Figure 4 The effect of omeprazole and chloroquine on the toxicity of doxorubicin (A and C) and mitoxantrone (B and D) for EMT-6 (A and B) and
MCF-7 (C and D) cells as determined by a clonogenic assay. Doxorubicin alone (K), mitoxantrone alone (’), drug plus chloroquine 100mM (m)o r
omeprazole 100mM (.). Mean and s.e.m. are shown for three independent experiments. Chloroquine and omeprazole showed no cytotoxicity when used
alone.
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Figure 5 Penetration of radiolabelled doxorubicin (A and C) and mitoxantrone (B and D) through MCL derived from EMT-6 (A and B) and MCF-7 (C
and D) cells relative to that through the Teflon membrane alone at each time interval. MCL were exposed to doxorubicin alone (K), mitoxantrone alone
(’) or drug plus omeprazole 100mM (.). Mean and s.e.m. are shown for three independent experiments.
Modifiers of endosomal sequestration of basic anticancer drugs
CM Lee and IF Tannock
867
British Journal of Cancer (2006) 94(6), 863–869 & 2006 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sWe elected to study chloroquine and omeprazole because they
are in clinical use (for treatment of malaria and ulcer disease,
respectively) and because quite high doses are tolerated in vivo
(Lambers et al, 1984; Onyeji and Ogunbona, 2001). This would
allow the rapid transfer of encouraging laboratory data to
evaluation in a clinical trial. Bafilomycin A is not an agent that
could be used clinically, but was included as a specific inhibitor of
the endosomal proton pump.
The two cell lines used in these experiments express at most low
levels of P-glycoprotein (data not shown) and are moderately
sensitive to doxorubicin and mitoxantrone (Figure 4). However,
contrary to the findings of Altan et al (1998), these cells contained
acidified endosomes (Figure 1) and the basic drug doxorubicin
localized within them (Figure 2). Each of the modifying agents
increased endosomal pH in a dose-dependent manner in the two
malignant cell lines that were studied (Figure 1). As expected,
this was achieved at a lower concentration of bafilomycin A
(B100nM), while concentrations of 100mM chloroquine or 1mM
omeprazole were needed to achieve the same effect. We expected
less trapping of basic drugs in endosomes with raised pH and
confirmed that there was direct correlation between the ability of
modifying agents to raise endosomal pH and to reduce doxo-
rubicin fluorescence in endosomes.
When basic anticancer drugs enter cells, there is likely to be
competition for uptake into endosomes and into the nucleus. We
have confirmed colocalisation of fluorescent doxorubicin with a
fluorescent lysosomal probe, although the method does not allow
quantitative comparison of drug concentration among cellular
compartments because of the effect of different physical properties
(e.g. pH) and binding (e.g. to DNA). We hypothesised that if
uptake into endosomes was inhibited, either more drug would be
available to the nucleus, leading to greater toxicity for a given level
of cellular uptake, or (if equilibrium was achieved) there would be
a decrease in net cellular uptake without change in the amount of
drug reaching the cell nucleus or in cytotoxicity. We found that the
modifiers caused relatively small changes in net cellular uptake of
the anticancer drugs, so that concentrations of omeprazole and
chloroquine that inhibit uptake of anticancer drugs into endo-
somes probably cause redistribution of doxorubicin and mito-
xantrone within the cell. Chloroquine is also known to be an
inhibitor of DNA repair, and there is recent evidence that it can
upregulate p53-mediated apoptosis (Mohamed, 2005). We found
that chloroquine had minimal effects on the cytotoxicity of the
anticancer drugs (despite reduced net cellular uptake of doxo-
rubicin), whereas concentrations of omeprazole or bafilomycin A
that showed no cytotoxicity when used alone increased the
cytotoxicity of the anticancer drugs (Figure 4). Whether the effect
of omeprazole to increase cytotoxicity might be useful clinically
would depend on relative effects against tumour and dose-limiting
normal tissues.
Our third hypothesis, that the modifiers might improve the poor
penetration of doxorubicin and mitoxantrone through tumour
tissue was based on previous studies indicating that drug
penetration was largely through the extracellular space and that
mechanisms that decreased cellular uptake of drugs improved
their tissue penetration (Tunggal et al, 2000; Cowan and Tannock,
2001). Decreased uptake of basic drugs into endosomes might be
expected to lead to a decrease in the their total cellular
accumulation, although endosomes are also known to fuse with
the cell membrane and deposit their contents extracellularly
(Schindler et al, 1996; Simon, 1999), so this will depend on the rate
of endosomal recycling. The net uptake of doxorubicin, but not
mitoxantrone was reduced by coadministration of either chloro-
quine or omeprazole (Figure 3), although effects of omeprazole
were observed at doses below those found to have an effect on
endosomal pH, which might be due to other mechanisms. There
was no effect of bafilomycin A on cellular uptake of the anticancer
drugs. Chloroquine is not only a weak base but also a known
(if relatively poor) inhibitor of P-glycoprotein (Beck et al, 1988;
Riffkin et al, 1996); hence, part of its effect to decrease cellular
uptake of doxorubicin might be due to increased export across the
cellular membrane.
We would expect improved penetration of anticancer drugs
under conditions when net cellular uptake is inhibited, and our
measured effects on cellular uptake were inconsistent and smaller
than we had originally anticipated. We did find effects to improve
tissue penetration using the MCL model, although these results
were cell line-dependent and correlated imperfectly with the
influence of the modifiers on net cellular uptake of the anticancer
drugs. It is evident that multiple factors influence tissue
penetration, including not only drug uptake but also unknown
effects of modifying agents on the extracellular environment.
Nonetheless, the demonstration of an ability to improve tissue
penetration using strategies that enhance or maintain cytotoxicity
to proximal cells has potential application to improve therapeutic
index, since limited tissue penetration is unlikely to occur in well-
vascularised dose-limiting normal tissues such as the bone
marrow. The application of these results to improving tissue
penetration in vivo will depend on additional factors, including
the tissue penetration of the modifiers themselves. We have
established recently a method of quantifying tissue gradients of
doxorubicin from blood vessels in solid tumours (Primeau et al,
2005), and will investigate the use of modifying agents studied
here to change those distributions in tumours. The effects on
therapeutic index will depend also on the relative importance of
quiescence vs limited drug distribution in leading to resistance of
distal cells, and on possible effects of modifiers to redistribute
anticancer drugs in cellular compartments of normal cells, thereby
increasing toxicity.
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